The Headline Number: What It Actually Means
"Ten million times more potent than BDNF" is the claim most associated with Dihexa in nootropic research discussions. This number is real, published, and peer-reviewed — but it describes something specific that's often misunderstood.
The figure comes from a 2013 paper by Joseph Harding and colleagues at Washington State University (published in *The Journal of Pharmacology and Experimental Therapeutics*), comparing the concentration required to produce synaptogenesis (the formation of new synaptic connections) in cell culture assays:
The difference: 10 million fold.
What it means: In the specific assay measuring synapse formation, Dihexa produced the effect at a concentration 10 million times lower than BDNF. This is a comparison of concentration-required for a specific in vitro effect — not a claim that Dihexa is 10 million times more effective than BDNF in any clinical sense.
BDNF and Dihexa also work through different receptors. This potency comparison is essentially saying they are not equivalent molecules — Dihexa's receptor engagement produces synaptogenic signaling at dramatically lower concentrations in cell culture. Whether this translates to dose-equivalent clinical potency is a separate question the research has not fully answered.
What Dihexa Is
Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is a synthetic hexapeptide analog of Angiotensin IV — a metabolite of the renin-angiotensin system. It was developed by researchers at Washington State University, particularly by Joseph Harding's group, as part of a program studying the cognitive effects of the angiotensin system.
The key mechanism: Dihexa potentiates HGF (hepatocyte growth factor) signaling through c-Met — the HGF receptor. HGF/c-Met is a growth factor pathway involved in tissue repair, cell migration, and — critically for Dihexa's interest — synaptic plasticity and neuronal survival.
The HGF/c-Met Mechanism in the Brain
Hepatocyte Growth Factor was originally named for its role in liver regeneration, but HGF receptors (c-Met) are expressed throughout the brain, particularly in:
HGF/c-Met signaling in the brain promotes:
Dihexa does not simply agonize c-Met — it potentiates HGF binding to c-Met, making endogenous HGF more effective. This indirect potentiation mechanism means Dihexa amplifies an existing natural growth factor signal rather than replacing it.
The Animal Research
The 2013 Washington State paper, and subsequent work, showed in rodent models:
Cognitive performance: Dihexa-treated aged rats (a model of age-related cognitive decline) showed significant improvements in water maze performance — a standardized spatial memory test — compared to controls. The improvements approached performance levels of young adult rats.
Parkinson's model: In rodent 6-OHDA lesion models (a standard Parkinson's model), Dihexa protected dopaminergic neurons and improved motor function outcomes.
Ischemic injury: In stroke models, Dihexa treatment showed neuroprotective effects and improved functional recovery.
Oral bioavailability: A notable pharmacokinetic property — Dihexa is orally bioavailable and penetrates the blood-brain barrier, which is unusual for peptides of its size. This property made oral capsule administration a viable research route, unlike most peptides which require injection for CNS effects.
The Oral Bioavailability Advantage
Most peptides are degraded in the GI tract before reaching circulation in active form, and those that do reach circulation typically cannot cross the blood-brain barrier. Dihexa's pharmacokinetic profile is unusual:
The capsule forms (5 mg and 10 mg) enable research protocols without injection, a meaningful practical advantage for cognitive research applications.
Evidence Limitations and Research Gaps
The Dihexa research landscape as of 2026:
Strengths:
Gaps:
The absence of human data is a significant caveat. The compound's strong preclinical profile and unique mechanism have generated considerable research interest, but the translation to human cognitive outcomes remains uncharacterized.
Research Protocol Notes
Because Dihexa works through a growth factor potentiation mechanism rather than receptor desensitization, prolonged continuous use protocols are more common in research contexts than short cycles.
Important Note
This article is for educational and research reference purposes only. Dihexa has not been evaluated in human clinical trials and is not FDA-approved for any indication. The "10 million times more potent than BDNF" figure reflects a specific in vitro assay comparison and should not be interpreted as a clinical potency claim. All information presented here is for research reference and is not medical advice.